Early Neurological Deterioration in Patients With Acute Ischemic Stroke

NCT ID: NCT03703986

Last Updated: 2019-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-20

Study Completion Date

2019-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study set out to explore the risk factors of early neurological deterioration (END) occurred in patients with acute ischemic stroke and to investigate the corresponding predictors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

END refers to the illness aggravation occurred in the early stage of stroke and often indicates a poor outcome. Some clinical scales may play an important role in its diagnoses and treatments. Across the reviewed studies, the risk factors of END, which included biochemical parameters, neuroimaging, ect. were explored incompletely and the effective predictors of END is unknown. We aimed to explore the risk factors of END and investigate the predictive value of certain scales.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

END group

The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.

No interventions assigned to this group

non-END group

The patients in this group had a slight increase of \< 2 points or a decrease in NIHSS within 7 days of stroke onset.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with acute ischemic stroke
* Subjects with detailed progress notes

Exclusion Criteria

* Subjects with thrombolysis therapy
* Subjects with transient ischemia attach
* Subjects complicated with seriously underlying diseases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The First Affiliated Hospital with Nanjing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affiliated Hospital of Nanjing Medical University

Nanjing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hong Cheng, MD

Role: CONTACT

+0086 2583674680

Mei Sun, MD

Role: CONTACT

+0086 18651316588

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hong Cheng

Role: primary

008613815877695

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-SR-099

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.